GetTopicDetailResponse(id=63cd1e27025, topicName=Tenapanor, introduction=Tenapanor, content=null, image=null, comments=3, allHits=1112, url=https://h5.medsci.cn/topic?id=17270, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=60818, tagList=[TagDto(tagId=60818, tagName=Tenapanor)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1755547, encodeId=729a1e55547ab, content=<a href='/topic/show?id=63cd1e27025' target=_blank style='color:#2F92EE;'>#Tenapanor#</a>, objectTitle=Ardelyx的鈉/氫交換異構(gòu)體抑制劑tenapanor符合高磷血癥的III期研究的主要終點, objectType=article, longId=178809, objectId=55521e880970, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55521e880970, replyNumber=0, likeNumber=84, createdTime=2019-10-08, rootId=0, userName=ying_wu, userId=303f36951557, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55521e880970, moduleTitle=Ardelyx的鈉/氫交換異構(gòu)體抑制劑tenapanor符合高磷血癥的III期研究的主要終點, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=55521e880970)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755548, encodeId=6a981e55548f3, content=<a href='/topic/show?id=63cd1e27025' target=_blank style='color:#2F92EE;'>#Tenapanor#</a>, objectTitle=Ardelyx的實驗性藥物Tenapanor達到了高磷血癥的第二個III期研究的主要目標, objectType=article, longId=184167, objectId=053a18416e94, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=053a18416e94, replyNumber=0, likeNumber=120, createdTime=2020-03-17, rootId=0, userName=ying_wu, userId=303f36951557, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=053a18416e94, moduleTitle=Ardelyx的實驗性藥物Tenapanor達到了高磷血癥的第二個III期研究的主要目標, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=053a18416e94)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755546, encodeId=36541e55546a9, content=<a href='/topic/show?id=63cd1e27025' target=_blank style='color:#2F92EE;'>#Tenapanor#</a>, objectTitle=Ardelyx重磅藥物tenapanor（NHE3受體抑制劑）二期臨床試驗失利, objectType=article, longId=50383, objectId=d6d7503835f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6d7503835f, replyNumber=0, likeNumber=98, createdTime=2016-04-05, rootId=0, userName=ying_wu, userId=303f36951557, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6d7503835f, moduleTitle=Ardelyx重磅藥物tenapanor（NHE3受體抑制劑）二期臨床試驗失利, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=d6d7503835f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
